Repotrectinib effective in ROS1-fusion-positive NSCLC

IF 81.1 1区医学 Q1 ONCOLOGY Nature Reviews Clinical Oncology Pub Date : 2024-01-26 DOI:10.1038/s41571-024-00864-4

Peter Sidaway

引用次数: 0

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

瑞博替尼对ROS1融合阳性NSCLC有效

携带ROS1融合的晚期非小细胞肺癌（NSCLC）患者（约占患者总数的1-2%）可以从ROS1酪氨酸激酶抑制剂（TKIs）中获益，如恩替替尼（entrectinib）或克唑替尼（crizotinib）。然而，这些药物的获得性耐药性很常见，而且对中枢神经系统的活性往往有限。现在，一项大型队列I/II期试验TRIDENT-1的数据证明了第二代ROS1 TKI repotrectinib的安全性和有效性，无论是在TKI非特异性患者还是在TKI治疗后的ROS1融合阳性NSCLC患者中都是如此。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Nature Reviews Clinical Oncology 医学-肿瘤学

CiteScore

99.40

自引率

0.40%

发文量

114

审稿时长

6-12 weeks

期刊介绍： Nature Reviews publishes clinical content authored by internationally renowned clinical academics and researchers, catering to readers in the medical sciences at postgraduate levels and beyond. Although targeted at practicing doctors, researchers, and academics within specific specialties, the aim is to ensure accessibility for readers across various medical disciplines. The journal features in-depth Reviews offering authoritative and current information, contextualizing topics within the history and development of a field. Perspectives, News & Views articles, and the Research Highlights section provide topical discussions, opinions, and filtered primary research from diverse medical journals.